Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Subscribe To Our Newsletter & Stay Updated
